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Abstract
Background: The aim of the study is to evaluate the role of cytoreductive nephrectomy (CN) with thrombectomy
before targeted molecular therapy (TMT) on survival in metastatic renal cell carcinoma (mRCC) with venous tumor
thrombus.
Methods: We performed a retrospective analysis of 47 patients treated in our center from April 2008 to October
2014. In the study, 20 patients underwent CN with thrombectomy followed by targeted therapy (group 1); 15
patients received targeted therapy alone (group 2); and 12 patients underwent CN with thrombectomy alone
(group 3). The overall survival (OS) and cancer-specific survival (CSS) were calculated according to the Kaplan-Meier
survival curve method, and prognostic variables were assessed by Cox regression analyses.
Results: The median follow-up times of group 1, group 2, and group 3 were 24.5, 12, and 6.5 months, respectively.
During follow-up, in both group 1 and group 3, 12 patients died. In group 2, 14 patients died. The median OS of
group 1, group 2, and group 3 was 22, 12, and 6 months, respectively (P < 0.001). Compared with surgery alone and
targeted therapy alone, patients with cytoreductive surgery before targeted therapy had statistically better survival
benefits (P < 0.001, P = 0.009, respectively). On univariate analysis, the number of metastatic sites (P = 0.004) was a
statistically significant prognostic factor influencing OS.
Conclusions: Our single-center experience showed that CN with thrombectomy before targeted therapy improved
the survival of patients with mRCC with venous tumor thrombus. The number of metastatic sites was an
independent prognostic factor influencing OS.
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Background
Venous tumor thrombus (VTT) occurs in approximately
5–10% of patients undergoing nephrectomy for renal
cell carcinoma (RCC) [1]. In addition to venous involve-
ment, 25% of patients with RCC have metastatic disease
when diagnosed [2]. Patients with RCC and VTT should
be considered for surgical intervention, irrespective of
the extent of tumor thrombus at presentation [3]. Before
the era of targeted therapy, two prospective randomized
controlled trials had demonstrated the overall benefit of
cytoreductive nephrectomy (CN) in metastatic RCC [4, 5].
A population-based study also showed the beneficial effect
of CN on survival [6]. The emerging of targeted therapy
offers more choices for mRCC and has prompted a reeval-
uation of cytoreductive surgery [7]. Tyrosine kinase inhibi-
tor (TKI) had been shown to extend the progression-free
survival and overall survival [8]. Differential expression of
prognostic proteomic markers, such as VEGFR1, was
found in primary tumor, VTT, and metastatic renal cell
cancer tissue [9], suggesting that TKI alone may help im-
prove the survival of mRCC with VTT.
Although CN with inferior vena cava (IVC) thrombec-
tomy was performed with acceptable complication rates
[10], it remains unclear whether surgery is still a good choice
for concomitant mRCC with VTT. Thus, we retrospectively
evaluated the benefits of CN with thrombectomy before tar-
geted therapy in patients presenting with mRCC withVTT.
Methods
We reviewed the medical records of all patients who
presented to our center from April 2008 to October
2014 for evaluation of or treatment for concomitant
mRCC with VTT. During the study period, 61 patients
presented with concomitant mRCC with VTT who had
received no systemic therapy. Among them, 20 patients
underwent CN with thrombectomy followed by TMT
(combined therapy, group 1); 15 patients received TMT
alone (group 2); 12 patients underwent CN with
thrombectomy alone (group 3); and 2 refused any
therapy. The treatment of the other 12 patients was un-
certain. Patients in group 1, group 2, and group 3 had
postoperative pathology or biopsy confirmed of RCC
histology. Metastasis was confirmed by radiology. The
following clinical characteristics of each patient were
recorded: age, gender, ECOG PS (Eastern Cooperative
Oncology Group performance score), tumor size,
pathologic type, nuclear grade, venous thrombus level,
number of metastatic sites, T stage and N stage. These
characteristics were potential prognostic factors [11–14].
Staging was determined according to the 2009 AJCC sta-
ging system [15]. Nuclear grade was graded using the
Fuhrman grading system [16]. Venous tumor extent was
graded according to the Mayo Clinic grading system
[17]. Nineteen patients received sorafenib (18 cases as
first-line therapy and 1 case as second-line therapy fol-
lowing sunitinib). Sorafenib was administered at a dose
of 400 mg twice daily and continued until disease pro-
gression or the onset of an intolerable adverse drug
event. The 19 patients received sunitinib (16 cases as
first-line therapy and 3 cases as second-line therapy fol-
lowing sorafenib). Sunitinib was administered at a dose
of 50 mg once daily for 4 weeks, followed by 2 weeks off
by repeated 6-week cycles. All the 19 patients were
treated continuously until disease progression or un-
acceptable toxicities occurred. Pazopanib monotherapy
was administered at a dose of 800 mg once daily in 1 pa-
tient. No neoadjuvant targeted therapy was used. In-
formed consent was obtained from all individual
participants included in the study. The study was ap-
proved by the institutional review board from Peking
University First Hospital.
Statistical analysis
Likelihood ratio with chi-square and t tests was used for
comparisons between groups in categorical and continu-
ous variables, respectively. OS (overall survival) and CSS
(cancer-specific survival) curves were derived by the
Kaplan-Meier method with the log-rank test. Each group
was further compared with Kaplan-Meier curve. Univar-
iate Cox hazards regression were applied to evaluate the
value of prognostic factors including advanced age, gen-
der, ECOG PS, pathological type, nuclear grade, venous
thrombus level, T stage, N stage, and number of
metastatic sites in predicting OS and CSS. All statistical
analyses were performed using SPSS version 19 (SPSS
Inc., Chicago, IL, USA). Statistical significance was set at
P < 0.05.
Results
Table 1 shows patient clinicopathological characteristics
at diagnosis. The median age of group 1, group 2, and
group 3 were 55(20–70), 58(26–72), and 61(46–71)
years, respectively. There were no significant differences
except gender, ECOG PS, nuclear grade, N stage, and
number of metastatic sites. In group 1, 10 patients were
T3a; 5 patients were T3b. The number of level 0, level
II, and level III thrombus was 12, 5, and 3, respectively.
Lung metastasis, liver metastasis, bone metastasis, and
adrenal metastasis appeared in 12, 4, 3, and 2 patients,
respectively. In group 2, 4 patients were T3a; 8 patients
were T3b. The number of level 0, level I, level II, and level
III thrombus was 4, 1, 3 and 7, respectively. Lung metasta-
sis, liver metastasis, adrenal metastasis, bone metastasis,
and pleura metastasis appeared in 10, 5, 4, 3, and 2
patients, respectively. In group 3, 7 patients were T3a; 1
patient was T3b; 1 patient was T3c. The number of level
0, level I, level III, and level IV thrombus was 9, 1, 1 and 1,
respectively. Lung metastasis, bone metastasis, liver
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metastasis, and adrenal metastasis appeared in 9, 3, 1, and
1 patient, respectively.
The median follow-up time of group 1, group 2, and
group were 24.5 (range 3–66), 12 (range 2–33), and 6.5
(range 3–30) months. During follow-up, 12 patients died
in both group 1 and group 3. Fourteen patients died in
group 2. The median OS of group 1, group 2, and group 3
was 22 (95% CIs 4.5–39.5), 12 (95% CIs 3.2–20.8), and 6
(95% CIs 4.3–7.7) months, respectively (P < 0.001, Fig. 1).
The median CSS of group 1, group 2, and group 3 was 45,
19, and 8 months, respectively (P < 0.001, Fig. 2). The me-
dian progression-free survival of group 1 and group 2
were 12 (range 1–66) and 9 (range 2–23) months, respect-
ively. Compared with patients who underwent surgery
alone or targeted therapy alone, patients with
cytoreductive surgery before targeted therapy had statisti-
cally better overall survival benefits (P < 0.001 and P =
0.009, respectively). Patients with combined therapy also
had better CSS benefits. In a univariate Cox proportional
hazards model to predict OS, we found that the number
of metastatic sites was a significant predictor of OS
(Table 2). Compared with patients with solitary metas-
tasis, patients with more than one metastatic site had
a 2.94-fold higher risk of overall mortality (95% CIs
1.41–6.09, P = 0.004). However, the number of metas-
tasis did not affect the probability of CSS (Table 2).
One patient in group 1 achieved complete remission.
None of patients in group 2 achieved complete remis-
sion. The median treatment duration of sorafenib was
8 months. Adverse events were shown in Table 3. Most
of them were grade 1–2 adverse events. The grade 3–4
major adverse events (4 cases) included hand-foot syn-
drome (2 cases), rash (1 case), and fatigue (1 case). All of
them kept treatment with symptomatic support. The
median treatment duration of sunitinib was 12 months. Ad-
verse events were shown in Table 4. The grade 3–4 major
adverse events (7 cases) included thrombocytopenia (3
cases), leukocytopenia (2 cases), hand-foot syndrome (1
case), and thyroid dysfunction (1 case). Six patients had dose
decrement or drug discontinuation. All of them kept treat-
ment with symptomatic support. The patient treated with
pazopanib emerged with hand-foot syndrome, nausea, and
vomit during treatment. After 16 months, he progressed
with lung metastasis and withdrew from treatment.
Discussion
The combination of CN and systemic therapy plays an
important role in the management of patients with
mRCC. Retrospective studies suggest that mRCC pa-
tients with IVC tumor thrombus may experience im-
proved survival after surgical resection and systemic
therapy. These studies were conducted before the
current era of targeted therapy, which, at present, repre-
sent a standard therapy for mRCC. In the era of targeted
therapy, few researches explored this problem. Taekmin
Kwon et al. found that surgical resection of the primary
renal mass with IVC thrombus before use of TKI did
not affect the overall mortality [18]. Conversely, Karin E
et al. suggested that CN with IVC thrombectomy should
be considered as an integral part of the treatment ap-
proach for patients with mRCC with IVC tumor thrombi
[10]. However, proper treatment of mRCC with VTT has
yet to be determined. Our study showed that compared
with surgery alone and targeted therapy alone, cytore-
ductive surgery before targeted therapy improved the
overall survival and cancer-specific survival of mRCC
with VTT.
The prognosis was quite poor for the majority of pa-
tients with RCC with VTT when left untreated,
Table 1 Patient demographics of group 1, group 2, and group 3
Group 1 Group 2 Group 3 P
No 20 15 12
Gender, n (%) 0.590a,0.022b
Male 15(75.0%) 10(66.7%) 12(100%)
Female 5(25.0%) 5(33.3%) 0(0%)
Age, n (%) 0.486a,0.197b
≥60 7(35.0%) 7(46.7%) 7(58.3%)
<60 13(65.0%) 8(53.3%) 5(41.7%)
Pathologic type, n (%) 1.000a,0.360b
Clear cell 16(80.0%) 12(80.0%) 11(91.7%)
Non-clear cell 4(20.0%) 3(20.0%) 1(8.3%)
Nuclear grade, n (%) 0.005a,0.488b
G1 + G2 3(15.0) 9(60.0%) 3(25.0%)
G3 + G4 17(85.0%) 6(40.0%) 9(75.0%)
VT level, n (%) 0.039a,0.900b
Above hepatic vein 3(15.0%) 7(46.7%) 2(16.7%)
Below hepatic vein 17(85.0%) 8(53.3%) 10(83.3%)
Tumor size, (cm ± SD) 9.9 ± 2.4 10.8 ± 4.0 9.8 ± 1.8 0.439a,0.903b
T stage, n (%) 0.726a,1.000b
T3 15(75.0%) 12(80.0%) 9(75.0%)
T4 5(25.0%) 3(20.0%) 3(25.0%)
N stage, n (%) 0.061a,0.252b
N0 13(65.0%) 5(33.3%) 10(83.3%)
N1 7(35.0%) 10(66.7%) 2(16.7%)
Number of metastatic sites, n (%) 0.001a,0.586b
1 18(90.0%) 6(40.0%) 10(83.3%)
>1 2(10.0%) 9(60.0%) 2(16.7%)
ECOG PS 0.015a,0.742b
0 16(75.0%) 6(40.0%) 9(75.0%)
1 4(25.0%) 9(60.0%) 3(25.0%)
aComparison between group 1 and group 2
bComparison between group 1 and group 3
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especially for those with metastases. In patients present-
ing with metastatic disease, 1-year DSS (disease-specific
survival) was 23% (median DSS: 4 months) for those
with thrombus below the diaphragm and 10% (median
DSS: 3 months) for those with thrombus above the
diaphragm [19]. For those with distant metastases at the
time of diagnosis who underwent surgery, 1-year
survival was 60%. This finding highlighted the import-
ance of surgery on their prognosis. With the develop-
ment of surgical skills, novel anesthetic technique, and
hemodynamic monitor, the perioperative mortality and
complications associated with nephrectomy with thromb-
ectomy decreased to an acceptable level [17, 20]. In some
patients, surgery may help to relieve symptoms. However,
the surgery was still challenging, and surgery-related mor-
bidity or mortality could not be neglected. Bissada et al.
reported higher perioperative mortality in patients with
metastasis (33%) versus patients without metastasis (2%)
[21]. Fortunately, all of the 32 patients survived surgery in
our center. However, some patients may undergo disease
progression during recovery from surgery and may not
proceed to receive systemic therapy for their metastatic
tumor burden [22]. In fact, we observed that some pa-
tients failed to receive targeted therapy after surgery for
several reasons. Silberstein et al. [23] have demonstrated
that patients with poor performance status are more likely
to experience postoperative complications, and these pa-
tients tend not to receive systemic therapy on time after
surgery. Culp et al. [24] identified seven risk factors that
predicted inferior OS after CN, including high lactate de-
hydrogenase activity, low albumin level, symptoms caused
by metastatic disease, liver metastasis, retroperitoneal ade-
nopathy, supradiaphragmatic adenopathy, and a greater
than cT3 disease. Patients with ≥4 risk factors did not ap-
pear to benefit from CN. Based on the present study, it
seems that patients’ general condition and performance
status should be used to best define candidates for CN
with VTT. While the risk of perioperative complications
outweighed the potential benefits, cytoreductive surgery
should not be the first option considered.
Fig. 1 Overall survival of group 1, group 2, and group 3
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On univariate Cox regression analysis, pathologic type,
nuclear grade, and venous tumor thrombus level were
not significantly associated with survival. In contrast,
more than one metastatic site was an independent prog-
nostic factor of a poor OS. In fact, a previous study had
already shown that the number of metastatic sites
affected the survival rates of the patients with mRCC
[25]. This may be owing to the more disease burden and
worse functional status. More studies are needed to help
ameliorate the poor prognosis.
Our study had some limitations. The number of pa-
tients was low and follow-up time was short. Because of
Fig. 2 Cancer-specific survival of group 1, group 2, and group 3
Table 2 Univariate analysis of potential prognostic factors for OS and CSS
Univariate for OS Univariate for CSS
Variables HR(95% CI) P value HR(95% CI) P value
Age (≥60 vs. <60) 1.56(0.82–2.96) 0.178 1.53(0.73–3.21) 0.256
Gender (female vs. male) 1.02(0.48–2.17) 0.958 1.07(0.45–2.51) 0.883
ECOG PS (1 vs. 0) 0.59(0.29–1.20) 0.145 0.64(0.29–1.41) 0.267
Pathological type (non-clear cell vs. clear cell) 0.71(0.28–1.83) 0.480 0.76(0.26–2.18) 0.605
Nuclear grade (G3 + G4 vs. G1 + G2) 0.84(0.43–1.64) 0.608 0.65(0.31–1.40) 0.273
VT level (above hepatic vein vs. below hepatic vein) 1.67(0.71–3.03) 0.302 1.36(0.58–3.20) 0.482
T stage (T4 vs. T3) 1.50(0.70–3.20) 0.294 1.63(0.69–3.87) 0.264
N stage (N1 vs. N0) 1.32(0.69–2.54) 0.407 1.63(0.77–3.47) 0.203
Number of metastatic sites (more than 1 vs. 1) 2.94(1.41–6.09) 0.004 2.14(0.86–5.34) 0.103
Combined therapy
TMT alone 2.69(1.20–6.02) 0.017 3.25(1.28–8.27) 0.013
Surgery alone 5.64(2.39–13.29) <0.001 7.05(2.60–19.11) <0.001
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its retrospective nature, the study lacked randomization
and has selection bias. Many factors may influence the
decision to undergo cytoreductive surgery before tar-
geted therapy. One obvious bias is that patients choosing
targeted therapy alone have a higher percentage of mul-
tiple metastatic sites. Pierorazio PM has already shown
that patients with widespread metastatic burden may
not benefit from surgery and are likely to choose conser-
vative management [26]. A population-based study
based on the surveillance, epidemiology, and end results
database revealed a similar result [27]. Some patients
even failed to receive targeted therapy after surgery for
various reasons. In additional, these patients had not
been resected of metastatic sites, even though complete
metastasectomy provides benefits in terms of OS, CSS,
and delay of systemic therapy [3]. Moreover, in our
study, the population was small, so we did not introduce
multivariable Cox analysis. Large-scale, randomized, and
prospective studies are needed to determine the effect
on survival of CN with thrombectomy before targeted
therapy.
Conclusions
Compared with cytoreductive surgery alone and targeted
therapy alone, CN with thrombectomy before targeted
therapy may offer better survival for mRCC with VTT.
Our single-center experience suggested a positive role
for cytoreductive surgery followed by targeted therapy in
these patients.
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